| scholarly article | Q13442814 |
| P50 | author | K G Smith | Q52055719 |
| Adrian G Torres | Q58868752 | ||
| Paul A Lyons | Q87690619 | ||
| Cei Abreu-Goodger | Q30093305 | ||
| Anton J. Enright | Q30502540 | ||
| P2093 | author name string | Donna Williams | |
| Michael J Gait | |||
| Elena Vigorito | |||
| Martin M Fabani | |||
| P2860 | cites work | Bioconductor: open software development for computational biology and bioinformatics | Q21194861 |
| Accumulation of miR-155 and BIC RNA in human B cell lymphomas | Q24556523 | ||
| Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas | Q24645617 | ||
| miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates | Q24647285 | ||
| Transfection and gene expression in normal and malignant primary B lymphocytes. | Q55241939 | ||
| Microwave-assisted Solid Phase Peptide Synthesis on High Loaded Resins | Q58102162 | ||
| Automated synthesis of peptide nucleic acids and peptide nucleic acid-peptide conjugates | Q74602771 | ||
| Rapid solid-phase peptide synthesis using thermal and controlled microwave irradiation | Q79762594 | ||
| Peptide nucleic acid synthesis by novel amide formation | Q80696542 | ||
| Single acute-dose and repeat-doses toxicity of anti-HIV-1 PNA TAR-penetratin conjugate after intraperitoneal administration to mice | Q80822794 | ||
| PNA: Synthetic Polyamide Nucleic Acids with Unusual Binding Properties | Q88519549 | ||
| Inositol phosphatase SHIP1 is a primary target of miR-155 | Q24648984 | ||
| Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder | Q24649158 | ||
| miRBase: tools for microRNA genomics | Q24649872 | ||
| MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways | Q24650451 | ||
| MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase | Q24653222 | ||
| Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF | Q24653834 | ||
| Requirement of bic/microRNA-155 for normal immune function | Q24656120 | ||
| Detecting microRNA binding and siRNA off-target effects from expression data | Q24658272 | ||
| Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells | Q24814987 | ||
| Linear models and empirical bayes methods for assessing differential expression in microarray experiments | Q27860758 | ||
| Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets | Q27860792 | ||
| Silencing of microRNAs in vivo with 'antagomirs' | Q27860891 | ||
| MicroRNA signatures in human cancers | Q27860962 | ||
| Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA | Q27861124 | ||
| PI3K in lymphocyte development, differentiation and activation | Q28187880 | ||
| miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting | Q29547487 | ||
| Regulation of the germinal center response by microRNA-155 | Q29547777 | ||
| Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection | Q29615959 | ||
| LNA-mediated microRNA silencing in non-human primates | Q29615962 | ||
| Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice | Q29619279 | ||
| microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells | Q29619307 | ||
| Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock | Q29619768 | ||
| Repression of protein synthesis by miRNAs: how many mechanisms? | Q29620361 | ||
| MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts | Q34521975 | ||
| miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression | Q34762601 | ||
| Cell penetrating peptide conjugates of steric block oligonucleotides | Q37013966 | ||
| Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids | Q40105838 | ||
| Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma. | Q40403348 | ||
| High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma | Q40660942 | ||
| Synthesis and purification of peptide nucleic acids | Q42168766 | ||
| Systemically delivered antisense oligomers upregulate gene expression in mouse tissues | Q44212614 | ||
| Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice | Q44264343 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 2.5 Generic | Q19113746 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | peptide nucleic acid | Q412152 |
| P304 | page(s) | 4466-4475 | |
| P577 | publication date | 2010-03-11 | |
| P1433 | published in | Nucleic Acids Research | Q135122 |
| P1476 | title | Efficient inhibition of miR-155 function in vivo by peptide nucleic acids | |
| P478 | volume | 38 |
| Q47246071 | A Peptide Nucleic Acid against MicroRNA miR-145-5p Enhances the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Calu-3 Cells |
| Q27300844 | Antagonistic Interplay between MicroRNA-155 and IL-10 during Lyme Carditis and Arthritis |
| Q47119028 | Anti-tumor Activity of miniPEG-γ-Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy. |
| Q38555602 | Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis? |
| Q37859009 | Antisense drug discovery and development |
| Q36540632 | Approaches to manipulating microRNAs in neurogenesis |
| Q38848213 | Biological Response Modifier in Cancer Immunotherapy |
| Q55638503 | Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics. |
| Q38251994 | Challenges and opportunities of microRNAs in lymphomas. |
| Q34200255 | Chemical modification and design of anti-miRNA oligonucleotides. |
| Q35823712 | Chemical structure requirements and cellular targeting of microRNA-122 by peptide nucleic acids anti-miRs |
| Q38833453 | Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells |
| Q50131778 | Covalent Strategies for Targeting Messenger and Non-Coding RNAs: An Updated Review on siRNA, miRNA and antimiR Conjugates. |
| Q64056999 | Current Progress on MicroRNA-Based Gene Delivery in the Treatment of Osteoporosis and Osteoporotic Fracture |
| Q38841033 | Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer |
| Q58001538 | Cytotoxic peptide–PNA conjugates obtained by RNA-programmed peptidyl transfer with turnover |
| Q28542002 | Delivery of antisense peptide nucleic acids to cells by conjugation with small arginine-rich cell-penetrating peptide (R/W)9 |
| Q38369597 | Delivery of therapeutic oligonucleotides with cell penetrating peptides. |
| Q90060069 | Demonstrating specificity of bioactive peptide nucleic acids (PNAs) targeting microRNAs for practical laboratory classes of applied biochemistry and pharmacology |
| Q59133148 | Design, synthesis and biochemical investigation, by in vitro luciferase reporter system, of peptide nucleic acids as new inhibitors of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression |
| Q48343656 | Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs |
| Q33991443 | Development of microRNA therapeutics is coming of age. |
| Q64092782 | Efficient cell penetration and delivery of peptide nucleic acids by an argininocalix[4]arene |
| Q38682574 | Environmental toxicants, incidence of degenerative diseases, and therapies from the epigenetic point of view |
| Q41451941 | Exploitation of a very small peptide nucleic acid as a new inhibitor of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression. |
| Q90400676 | Exploring miR-9 Involvement in Ciona intestinalis Neural Development Using Peptide Nucleic Acids |
| Q37648615 | Focus on PNA Flexibility and RNA Binding using Molecular Dynamics and Metadynamics. |
| Q37313310 | From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). |
| Q89472403 | In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge |
| Q37401124 | Incorporating a guanidine-modified cytosine base into triplex-forming PNAs for the recognition of a C-G pyrimidine-purine inversion site of an RNA duplex |
| Q21198757 | Inhibition of microRNA function by antimiR oligonucleotides |
| Q38294395 | Insights on chiral, backbone modified peptide nucleic acids: Properties and biological activity |
| Q36612260 | Mammalian alpha beta hydrolase domain (ABHD) proteins: Lipid metabolizing enzymes at the interface of cell signaling and energy metabolism |
| Q35863950 | MicroRNA delivery for regenerative medicine |
| Q38336334 | MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection. |
| Q38679814 | MicroRNA in the Diseased Pulmonary Vasculature: Implications for the Basic Scientist and Clinician. |
| Q35201318 | MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. |
| Q26747644 | MicroRNA therapeutics: Discovering novel targets and developing specific therapy |
| Q104135136 | MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK |
| Q43105077 | MicroRNA-155 controls affinity-based selection by protecting c-MYC+ B cells from apoptosis. |
| Q40376955 | MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis. |
| Q90188311 | MicroRNAs Determining Carcinogenesis by Regulating Oncogenes and Tumor Suppressor Genes During Cell Cycle |
| Q39455677 | Modulation of the biological activity of microRNA-210 with peptide nucleic acids (PNAs). |
| Q24595213 | Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma |
| Q26851250 | Non-coding RNAs as theranostics in human cancers |
| Q43642144 | PNA-based artificial nucleases as antisense and anti-miRNA oligonucleotide agents |
| Q35012045 | Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo |
| Q38176989 | Peptide nucleic acids: a review on recent patents and technology transfer |
| Q42226373 | Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. |
| Q26746968 | Peptides for nucleic acid delivery |
| Q92455541 | Physiological expression of miR-130a during differentiation of CD34+ human hematopoietic stem cells results in the inhibition of monocyte differentiation |
| Q89846275 | Poly(Lactic-co-Glycolic Acid) Nanoparticle Delivery of Peptide Nucleic Acids In Vivo |
| Q36004826 | Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing |
| Q39627292 | Porous Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies |
| Q39352033 | Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents |
| Q54967624 | Potent inhibition of miR-27a by neomycin-bisbenzimidazole conjugates. |
| Q60925900 | Potential of Peptide Nucleic Acids in Future Therapeutic Applications |
| Q39017832 | Probing of miniPEGγ-PNA-DNA Hybrid Duplex Stability with AFM Force Spectroscopy |
| Q37478933 | Progress in microRNA delivery |
| Q92753261 | RNA Secondary Structure-Based Design of Antisense Peptide Nucleic Acids for Modulating Disease-Associated Aberrant Tau Pre-mRNA Alternative Splicing |
| Q38242065 | RNA triplexes: from structural principles to biological and biotech applications |
| Q42325696 | Recent advances in chemical modification of Peptide nucleic acids |
| Q92891446 | Research advances in the detection of miRNA |
| Q38315145 | Sequence selective recognition of double-stranded RNA at physiologically relevant conditions using PNA-peptide conjugates |
| Q50233498 | Sequence-selective recognition of double-stranded RNA and enhanced cellular uptake of cationic nucleobase and backbone-modified peptide nucleic acids. |
| Q47655684 | Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids |
| Q50272660 | Single point mutation detection in living cancer cells by far-red emitting PNA-FIT probes. |
| Q92373604 | Specific Inhibition of Viral MicroRNAs by Carbon Dots-Mediated Delivery of Locked Nucleic Acids for Therapy of Virus-Induced Cancer |
| Q48270080 | Synthesis and Improved Cross-Linking Properties of C5-Modified Furan Bearing PNAs. |
| Q42269919 | Synthesis and Splice-Redirecting Activity of Branched, Arginine-Rich Peptide Dendrimer Conjugates of Peptide Nucleic Acid Oligonucleotides |
| Q64981432 | Targeting miR‑155‑5p and miR‑221‑3p by peptide nucleic acids induces caspase‑3 activation and apoptosis in temozolomide‑resistant T98G glioma cells. |
| Q35261089 | Targeting microRNA-122 to Treat Hepatitis C Virus Infection |
| Q36992190 | Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). |
| Q42321631 | Targeting pre-miRNA by peptide nucleic acids: a new strategy to interfere in the miRNA maturation. |
| Q36814052 | Temporal and spatial regulation of microRNA activity with photoactivatable cantimirs |
| Q35307418 | The miR-155-PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation |
| Q37900519 | The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy. |
| Q52743737 | Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities. |
| Q38249091 | Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers |
| Q38119545 | Therapeutic targeting of non-coding RNAs |
| Q60931361 | Tissue engineering strategies for the induction of angiogenesis using biomaterials |
| Q57299995 | Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis |
| Q39018554 | Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221. |
| Q38834594 | Versatility of peptide nucleic acids (PNAs): role in chemical biology, drug discovery, and origins of life |
| Q26746573 | miR-155 as a Biomarker in B-Cell Malignancies |
| Q37962609 | miRNA therapeutics: delivery and biological activity of peptide nucleic acids targeting miRNAs |
| Q38092617 | miRNA-Based Therapeutic Strategies |
| Q50544689 | microRNAs: Key Players in Hematopoiesis. |
Search more.